What ALEMBIC PHARMACEUTICALS LTD does

Alembic Pharmaceuticals Limited is a vertically integrated Indian pharmaceutical company, founded in 1907 and headquartered in Vadodara, with publicly listed status on BSE and NSE under ticker AP35 following a 2011 demerger from the Alembic group. The company operates three core business segments: India Formulations (specialty medicines across 10+ therapy areas including cardiovascular, dermatology, and chronic therapies for the domestic market), International Generics (regulated-market generic medicines with a US front-end established in 2015, distributing into 75+ countries), and Active Pharmaceutical Ingredients (vertically integrated API development and manufacturing for oncology, cardiovascular, diabetes, and antibiotics, serving both internal consumption and external global pharmaceutical customers). The business generates revenue through product sales across these three segments, with 17,000+ employees, 9 manufacturing facilities in the Vadodara cluster, 252 ANDA filings, and 132 DMF filings as primary scale indicators. Pricing operates through institutional/contract generic-pharma models that are not publicly disclosed, and go-to-market is sales-led with direct field sales in India, direct marketing capability in the US since 2015, and partner-based distribution in Europe, Canada, Australia, Brazil, and South Africa. Notable strategic assets include a 2017 US acquisition (Orit Laboratories LLC), a 2016 dermatology JV (Aleor Dermaceutical Limited with Orbicular), a 2019 China market JV, and an achieved US$250 million US front-end sales milestone by 2020. The company has developed an internal AI-powered employee assistant called Alembic Ask TARA, built on OpenAI's GEN-AI models and AWS infrastructure with multi-lingual Indian-language support, though this is an internal productivity tool rather than a product offering.

Name

ALEMBIC PHARMACEUTICALS LTD

Legal name

Alembic Pharmaceuticals Limited

Website

https://alembic-india.com

Company type

Public

Founded year

1907

Operating status

Operating

Headcount range

251–500 employees

Short description

Alembic Pharmaceuticals Ltd is a vertically integrated Indian pharmaceutical company that develops, manufactures, and markets generic formulations, APIs, and specialty medicines across India and 75+ international markets including the US, with 17,000+ employees, 9 manufacturing facilities, and 252 ANDA filings.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)

akta.pro secondary industries

Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO), Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO), Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF)

Keywords

• Generic drug manufacturing
• Active pharmaceutical ingredients
• Finished dosage formulations
• Complex generic development
• Pharmaceutical regulatory filings

Headquarters

HQ city

VADODARA

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

1. India Formulations: Domestic Indian market formulations business operating through multiple marketing divisions addressing chronic therapies including cardiovascular, dermatology, and other specialty medicines with strong brand recall among medical professionals.
2. International Generics: US and international regulated market generics business with strong US front-end. Company files ANDAs with USFDA, receives approvals, and commercializes products either directly or through partners. Revenue generated through product sales in US, EU, Australia, Brazil, Canada, and South Africa markets.
3. Active Pharmaceutical Ingredients (APIs): Vertically integrated API business developing in-house APIs for internal consumption and external sales to global pharmaceutical companies. Company develops and manufactures APIs for various therapeutic categories including oncology, cardiovascular, diabetes, and antibiotics.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Alembic develops, manufactures, and sells generic pharmaceuticals through India Formulations, International Generics, and Active Pharmaceutical Ingredients. Its offerings include in-house APIs, oral solids, liquid injectables, and topical products supplied to Indian healthcare customers, international pharmaceutical partners, and global API customers.

Product overview

Alembic Pharmaceuticals Ltd is a vertically integrated pharmaceutical company with three core business segments: India Formulations (specialty medicines for the domestic market), International Generics (global generic medicines with strong US presence including ANDAs and regulatory filings), and Active Pharmaceutical Ingredients (in-house API development and manufacturing for oncology, cardiovascular, diabetes, antibiotics and other therapeutic areas). The company operates 9 manufacturing facilities and has received 252 ANDA filings and 132 DMF filings. Alembic also developed an internal AI tool called 'Ask TARA' for employee assistance. The company was established in 1907, demerged from the Alembic group in 2011 and got listed, and has expanded internationally through JVs including Aleor Dermaceutical Limited for dermatology.

Differentiator

Problem solved

Functional benefit

Brands

• Aleor Dermaceutical Limited: Joint venture with Orbicular to develop dermatology products for the international market
• Althrocin
• Alembic Ask TARA

Products and services

• India Formulations Specialty and chronic-therapy medicines for the Indian domestic market, distributed through multiple marketing divisions for healthcare professionals and patients.
• International Generics Generic medicines commercialized in the US and other regulated markets, supported by ANDAs, regulatory filings, a direct US front-end, and international partnerships.
• Active Pharmaceutical Ingredients In-house active pharmaceutical ingredients developed and manufactured for internal formulation use and external sale to global pharmaceutical companies, including ingredients for oncology, cardiovascular, diabetes, and antibiotic medicines.
• Alembic Wikoryl range Cold and flu formulations based on Paracetamol with Chlorpheniramine Maleate and Phenylephrine Hydrochloride, offered as tablets, DS, oral drops, and oral suspension.
• Altoran 40/80 (Azilsartan) Azilsartan formulations offered in 40 mg and 80 mg strengths for hypertension management.
• Atecard D Cardiovascular medicine combining Atenolol IP and Chlorthalidone IP.
• Brozeet SF Respiratory medicine combining Ambroxol Hydrochloride IP, Guaiphenesin IP, and Terbutaline Sulphate IP.
• Cetanil Series (CT, M, O, T, Trio) Cilnidipine-based hypertension formulations combined with Chlorthalidone, Metoprolol Succinate, Olmesartan Medoxomil, or Telmisartan.
• Ciprowin Tz Anti-infective medicine combining Ciprofloxacin Hydrochloride with Tinidazole.
• Ephedrex/Ephedrex Plus Cough and cold formulations combining Chlorpheniramine Maleate, Dextromethorphan Hydrobromide, Phenylephrine Hydrochloride, and Ambroxol.
• Magadol Combination analgesic containing Diclofenac Sodium IP and Paracetamol IP for pain relief.
• Tellzy CH/RS Telmisartan-based combinations with Chlorthalidone and Rosuvastatin Calcium for hypertension and lipid management.
• Tetan CT Hypertension medicine combining Telmisartan and Chlorthalidone.
• Zeet Cough Formula/Zeet DX Cough remedies combining Ammonium Chloride, Diphenhydramine Hydrochloride, Sodium Citrate, and Dextromethorphan.
• Althrocin Alembic brand of Erythromycin launched in 1972; the source states that it became India's top-selling brand by 1997.
• Aripiprazole Aripiprazole pharmaceutical product launched in 2015 in connection with Alembic's establishment of the US front-end and transition to in-house US marketing.
• Pivya® Pharmaceutical product commercially launched in the United States, where its first prescription sale was reported in March 2026.

Quantifiable outcome

• US$ 250 million sales milestone achieved in US frontend by 2020
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature1 record

Partnerships

Four partnerships are on record, tiered minor and core.

• NATCO Pharma LtdminorStrategic or Co-development Partner · 1 January 2026Partnership for Olaparib Tablets 100mg and 150mg as reflected in press releases. Company markets products under NATCO partnership.
• China Market Joint VentureminorStrategic or Co-development Partner · 1 January 2019Entered a joint venture in 2019 to foray into the China market for pharmaceutical products.
• Orit Laboratories LLC, USAcoreStrategic or Co-development Partner · 1 January 2017Acquired Orit Laboratories LLC, USA in 2017 to expand US business operations and capabilities.
• Aleor Dermaceutical Limited (Orbicular JV)coreStrategic or Co-development Partner · 1 January 2016Joint venture struck with Orbicular to form Aleor Dermaceutical Limited for development of dermatology products for international market. Received USFDA approvals for Aleor's dermatology facility in 2018.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Cipla Limited: Major Indian pharmaceutical manufacturer with strong US generics franchise, South African presence, and Indian branded formulations across respiratory and chronic therapies. Closely comparable to Alembic on US ANDA pipeline, India domestic marketing structure, and API integration.
• Torrent Pharmaceuticals: Indian pharmaceutical company with strong presence in chronic therapies (cardiovascular, CNS, gastrointestinal) and active US generics business. Comparable to Alembic on India domestic focus on chronic/specialty branded formulations and US generic strategy.
• Zydus Lifesciences (Cadila Healthcare): Vertically integrated Indian pharma with US generics, India branded formulations, and API business. Similar to Alembic on full-stack operations, US ANDA pipeline, and India chronic-therapy focus, including biosimilars exposure.
• Glenmark Pharmaceuticals: Indian pharma with US generics, India branded formulations across dermatology, respiratory, and oncology, plus API operations. Comparable to Alembic on therapy-area overlap (especially dermatology), US generic strategy, and emerging-market expansion including Russia and Brazil.
• Aurobindo Pharma: Indian pharmaceutical company with substantial US generics franchise including injectables, oral solids, and APIs. Directly comparable to Alembic on US FDA-approved manufacturing scale, complex injectable expansion, and integrated API formulation model.
• Dr. Reddy's Laboratories: Vertically integrated Indian pharma company with significant US generics presence (including injectables and dermatology) and Indian formulations across cardiovascular and oncology. Directly comparable to Alembic on geographic footprint, dosage form breadth, and ANDA-driven US strategy.
• Lupin Limited: Indian pharma major with US generics, specialty, and API operations across cardiovascular, CNS, and anti-infective therapies. Comparable to Alembic on US regulatory filings pipeline, complex generics push (including ophthalmology and injectables), and emerging-market expansion.
• Sun Pharmaceutical Industries: India's largest pharmaceutical company with vertically integrated operations spanning generics, specialty, and API manufacturing across 100+ countries. Direct competitor to Alembic in US generic ANDAs, Indian branded formulations, and global API supply, with overlapping therapy areas including dermatology and oncology.

Broad incumbents

• Teva Pharmaceutical Industries: World's largest generic drug manufacturer with massive US generics portfolio and API capabilities. As a broad incumbent, Teva competes with Alembic on US generic products but operates at vastly greater scale across biosimilars, branded specialty, and OTC segments.
• Mylan (now Viatris): Global pharmaceutical company with extensive US and emerging-market generics footprint, including injectables, biosimilars, and APIs. As a broad incumbent, Viatris competes with Alembic in multiple US generic molecules and emerging-market distribution, though at significantly larger scale and product breadth.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/alembic-pharmaceuticals-ltd

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ALEMBIC PHARMACEUTICALS LTD